The Oncologist, Vol. 11, No. 3, 306-315, March 2006; doi:10.1634/theoncologist.11-3-306 © 2006 AlphaMed Press
The Role of Statins in Cancer Therapya Division of Cardiovascular Anesthesiology, Texas Heart® Institute, St. Lukes Episcopal Hospital, Houston, Texas, USA; b Department of Symptom Research and c Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA Key Words. HMG-CoA reductase inhibitor • Tumor • Chemotherapy • Inflammation • Prevention Correspondence: Charles D. Collard, M.D., Division of Cardiovascular Anesthesiology, The Texas Heart® Institute at St. Lukes Episcopal Hospital, 6720 Bertner Avenue, Room 0520, MC1-226, Houston, Texas 77030, USA. Telephone: 832-355-2666; Fax: 832-355-6500; e-mail: ccollard{at}heart.thi.tmc.edu
Administration of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, to ambulatory patients is associated with a lower incidence of long-term adverse cardiovascular events, including death, myocardial infarction, stroke, atrial fibrillation, and renal dysfunction. However, increasing clinical evidence suggests that statins, independent of their effects on serum cholesterol levels, may also play a potential role in the prevention and treatment of cancer. Specifically, statins have been shown to exert several beneficial antineo-plastic properties, including decreased tumor growth, angiogenesis, and metastasis. The feasibility and efficacy of statins for the prevention and treatment of cancer is reviewed.
This article has been cited by other articles:
Copyright © 2006 by AlphaMed Press. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||